
Early Treatment with New ALS Drug Combination Improved Survival
An open label extension shows additional benefit from a drug currently being tested for patients with Lou Gehrig’s disease.
An open label extension shows additional benefit from a drug currently being tested for patients with Lou Gehrig’s disease.
Positive clinical trial points to possible additional option for patients with Lou Gehrig’s disease. A study investigator explains the excitement and the caution.
When researchers study rare diseases, breakthroughs can be made that help patients. Revisit studies that are putting genetic puzzle pieces together to tackle these conditions.
A new study helps determine the role of legacy organochlorine pesticides and pollutants during the course of the progressive neurodeg
ALS is a debilitating, progressive disease without a cure. Researchers now find pesticides and other environmental toxins could play a part in the disease’s onset.